Results 141 to 150 of about 11,837 (160)

A pre-post quasi-experimental study of antimicrobial stewardship exploring the impact of a multidisciplinary approach aimed at attaining an aggressive joint pharmacokinetic/pharmacodynamic target with ceftazidime/avibactam on treatment outcome of KPC-producing Klebsiella pneumoniae infections and on

Antimicrobial Agents and Chemotherapy
To assess the impact of a multidisciplinary approach aimed at attaining aggressive joint pharmacokinetic/pharmacodynamic (PK/PD) target with ceftazidime/avibactam on treatment outcome of KPC-Klebsiella pneumoniae (Kp) infections and prevention of ...
Milo Gatti, M. Rinaldi, Piergiogio Cojutti, Cecilia Bonazzetti, A. Siniscalchi, T. Tonetti, S. Ambretti, S. Tedeschi, M. Giannella, P. Viale, F. Pea   +10 more
semanticscholar   +1 more source

Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study.

Lancet. Infectious Diseases (Print)
BACKGROUND Ceftolozane-tazobactam and ceftazidime-avibactam are preferred treatment options for multidrug-resistant Pseudomonas aeruginosa infections; however, real-world comparative effectiveness studies are scarce.
R. K. Shields, Lilian M. Abbo, Renee Ackley, Samuel L. Aitken, Benjamin Albrecht, Ahmed Babiker, Rachel Burgoon, Renzo Cifuentes, K. Claeys, Brooke N Curry, Kathryn DeSear, Jason C Gallagher, Esther Y. Golnabi, Alan E. Gross, Jonathan Hand, Emily L Heil, K. Hornback, Keith S Kaye, Trieu-Vi Khuu, Megan E Klatt, Ellen G. Kline, Ryan C. Kubat, W. Kufel, Jae Hyoung Lee, A. Lepak, Ahmi Lim, Justin Ludwig, C. MacDougall, Anjali Majumdar, Amy J Mathers, E. McCreary, William R Miller, M. Monogue, W. Moore, Shannon Olson, Jessica Oxer, J. Pearson, Christine Pham, Paulette Pinargote, C. Polk, M. Satlin, S. Satola, Sunish Shah, P. Tamma, T. Tran, D. van Duin, M. VanNatta, Ana Vega, V. Venugopalan, M. Veve, W. Wangchinda, Lucy S Witt, Janet Y. Wu, J. Pogue   +53 more
semanticscholar   +1 more source

Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam

Antimicrobial Agents and Chemotherapy
Few studies compare outcomes of patients with difficult-to-treat resistance (DTR) Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam.
Dariusz A. Hareza, Sara E. Cosgrove, R. Bonomo, Kathryn Dzintars, S. Karaba, A. Hawes, Tsigereda Tekle, P. Simner, P. Tamma   +8 more
semanticscholar   +1 more source

Ceftazidime-avibactam and aztreonam combination for Carbapenem-resistant Enterobacterales bloodstream infections with presumed Metallo-β-lactamase production: a systematic review and meta-analysis

Expert Review of Anti-Infective Therapy
Introduction Carbapenem-resistant Enterobacterales (CRE) due to Metallo-β-lactamase (MBL) production are treated with either polymyxins or the novel combination of ceftazidime-avibactam and aztreonam (AA). This study aims to evaluate the 30-day mortality
Nitin Gupta, Carl Boodman, P. Prayag, A. Manesh, T. P. Kumar   +4 more
semanticscholar   +1 more source

In vitro activity and genomic characterization of KPC-producing Klebsiella pneumoniae clinical blood culture isolates resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam: an Italian nationwide multicentre observational study (2022-23).

Journal of Antimicrobial Chemotherapy
OBJECTIVES To evaluate the in vitro activity of ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae (KPC-Kp) clinical isolates collected from a multicentre study in Italy (2022-23)
G. Bianco, M. Boattini, L. Lupo, Simone Ambretti, Rita Greco, Linda Degl’Innocenti, Sofia Chiatamone Ranieri, T. Fasciana, A. Mazzariol, Davide Gibellini, Guido Antonelli, Federica Sacco, A. Quirino, C. Farina, Bianca Paglietti, S. Comini, M. Fiamma, Francesco Broccolo, R. Cavallo, Cristina Costa, P. Gaibani   +20 more
semanticscholar   +1 more source

Ceftazidime/avibactam serum concentration in patients on ECMO.

Journal of Antimicrobial Chemotherapy
OBJECTIVES The use of extracorporeal membrane oxygenation (ECMO) may alter blood levels of several drugs, including antibiotics, leading to under dosing of these drugs and thus to potential treatment failure.
Anaïs Curtiaud, Matthieu Petit, J. Chommeloux, M. Pineton de Chambrun, G. Hékimian, Matthieu Schmidt, Alain Combes, C. Luyt   +7 more
semanticscholar   +1 more source

The pharmacokinetics/pharmacodynamics of ceftazidime/avibactam for central nervous system infections caused by carbapenem-resistant Gram-negatives: a prospective study.

Journal of Antimicrobial Chemotherapy
OBJECTIVES To describe the pharmacokinetics/pharmacodynamics (PK/PD) of ceftazidime/avibactam in critically ill patients with CNS infections. METHODS A prospective study of critically ill patients with CNS infections who were treated with ceftazidime ...
Ying Xu, Xuemei Luo, Binbin Yuan, Pei Liang, Ning Liu, Danjiang Dong, Weihong Ge, Qin Gu   +7 more
semanticscholar   +1 more source

An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients.

Journal of Antimicrobial Chemotherapy
OBJECTIVES Ceftazidime/avibactam is a key antibiotic for carbapenemase-producing Enterobacterales (CPE) Gram-negative infections, but current dosing may be suboptimal to grant activity. This study explores the population pharmacokinetics/pharmacodynamics
P. Cojutti, Manjunath P. Pai, Milo Gatti, M. Rinaldi, S. Ambretti, P. Viale, F. Pea   +6 more
semanticscholar   +1 more source

Mechanisms and fitness of ceftazidime/avibactam-resistant Klebsiella pneumoniae clinical strains in Taiwan.

International Journal of Antimicrobial Agents
BACKGROUND Carbapenem-resistant Klebsiella pneumoniae (CRKP) infection is a global public health issue, and ceftazidime/avibactam is recommended by international guidelines as the preferred treatment for KPC- and OXA-48-producing CRKP.
Sheng-Hua Chou, Chien Chuang, Chih-Han Juan, Yu-Chien Ho, Szu- Yu Liu, Liang Chen, Yi-Tsung Lin   +6 more
semanticscholar   +1 more source

The prevalence and mechanisms of heteroresistance to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae.

Journal of Antimicrobial Chemotherapy
OBJECTIVES To investigate the prevalence and mechanisms of ceftazidime/avibactam heteroresistance in KPC-producing Klebsiella pneumoniae (KPC-KP) isolates, as well as the role of heteroresistance in the transition of ceftazidime/avibactam susceptibility ...
Xiaotuan Zhang, Weiliang Zeng, Ji-Hye Kong, Zeyu Huang, Hongyun Shu, Miran Tang, Changrui Qian, Chunquan Xu, Tieli Zhou, Jianzhong Ye   +9 more
semanticscholar   +1 more source